Buoyed by Bumper Profits, WuXi Biologics Seeks to Bolster Global Supply Chain
Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would…
RELATED ARTICLES
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK -
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
